18 January 2022 - - US-based emerging biotechnology company GRO Biosciences Inc has appointed Rakhshita Dhar to its board of directors, the company said.

Dhar is an expert in life sciences platform development, business development, and pharmaceutical commercialization, with a background in search, evaluation and healthcare investing.

She is currently Senior director of Venture Investments Health at Leaps by Bayer.

Dhar received her Undergraduate degree in Biochemistry from Mumbai University and Master's in Molecular Biology from Georgetown University.

Dhar's past experience includes director of Business Development at Roche Pharmaceuticals where she led collaborations with Dyno Therapeutics and Rheos Biosciences.

She also spent several years at MassBio developing an accelerator program for life-science start-ups. Dhar serves as Senior director of Venture Investments Health at Leaps by Bayer.

GRO Biosciences is leveraging science to expand the amino acid alphabet and deliver on the promise of protein therapeutics.

The company is advancing treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients.

GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries.

The company's NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system.

GRObio, co-founded by Dr. George Church of Harvard Medical School in 2016, is headquartered in Cambridge, Massachusetts.